Joinn Laboratories (China) (HKG:6127, SHA:603127) agreed to provide certain services to Staidson (Beijing) Biopharmaceuticals (SHE:300204) group for 2025, a Friday Hong Kong bourse filing said.
Under the agreement, the company will provide professional and technical services and a comprehensive range of pharmaceutical research and development services to the Staidson Group.
The proposed annual cap for the services agreement is 50 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.